GSK2251052 in Complicated Urinary Tract Infection
This study has been terminated.
(Microbiological findings of resistance on therapy in patients with complicated urinary tract infection)
Information provided by (Responsible Party):
First received: June 9, 2011
Last updated: July 24, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been terminated.|
|Study Completion Date:||March 2012|
|Primary Completion Date:||March 2012 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||November 15, 2012|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
O'Dwyer K, Spivak AT, Ingraham K, Min S, Holmes DJ, Jakielaszek C, Rittenhouse S, Kwan AL, Livi GP, Sathe G, Thomas E, Van Horn S, Miller LA, Twynholm M, Tomayko J, Dalessandro M, Caltabiano M, Scangarella-Oman NE, Brown JR. Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 2015 Jan;59(1):289-98. doi: 10.1128/AAC.03774-14.